ClinicalTrials.gg
RecruitingNCT06638307Updated Nov 12, 2026

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

A Phase 1 interventional study of MEN2312 and Elacestrant in Advanced Breast Cancer, sponsored by Stemline Therapeutics, Inc.. Recruiting at 47 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Stemline Therapeutics, Inc. (part of Menarini Group) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.
Updated Nov 12, 20262 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Breast Neoplasms by Menarini Group — 4 open to participants now, 8 under way, 1 of them phase 3. Breast Neoplasms · Menarini Group.

Planned enrollment
4th of 12
240 · median 66
Started
2024
with 1 other
Phase 1
6 of 14
1 open now
Registered
12th of 14
by date

Among the 14 studies in Breast Neoplasms by Menarini Group, this one is the 4th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2024, is one of 6 in phase 1, and was the 12th registered.

Breast Neoplasms

14,840 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 14 studies in Breast Neoplasms by Menarini Group are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 2,398 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 590 (25%) stop at 75 or younger; 103 take children under 18; 213 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Breast Neoplasms by Menarini Group, or all of them as a file.
02

Study summary

This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.

03

Conditions studied

  • Advanced Breast Cancer

Browse trials for

Keywords

  • First-In-Human
  • MEN2312
  • Advanced Breast Cancer
  • KAT6
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participant has advanced (locoregionally recurrent or ) breast cancer not amenable to curative therapy.
  • Presence of genetic alterations in PIK3CA/AKT1/PTEN in participants' tumor tissue.
  • Participant must have received at least 1 prior line of endocrine therapy for advanced/metastatic disease or participant who has radiological evidence of breast cancer recurrence or progression during or within 12 months from the end of treatment with endocrine therapy, as these participants are considered as participants.
  • Progression on previous cyclin-dependent kinase 4 and 6 inhibitor treatment in combination with fulvestrant or aromatase inhibitor is required.

Key Exclusion Criteria:

  • Active or newly diagnosed central nervous system metastases.
  • Participants with advanced, symptomatic visceral spread, who are at risk of life-threatening complications in the short term, including massive uncontrolled effusions (peritoneal, pleural, pericardial), pulmonary lymphangitis, or liver involvement >50%.
  • Participants with any toxicities related to prior radiation therapy that have not resolved to baseline or to National Cancer Institute v5.0 Grade ≤1, except alopecia and peripheral sensory neuropathy (Grade ≤2).

Note: Other inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    MEN2312: Monotherapy

    Participants will receive MEN2312.

    Drug: MEN2312

  • Experimental
    MEN2312: Combination Therapy (Elacestrant)

    Participants will receive MEN2312 in combination with elacestrant.

    Drug: MEN2312 · Drug: Elacestrant

Interventions

  • DrugMEN2312

    MEN2312 administered as oral tablets.

  • Elacestrant administered as oral tablets.

    Also known as: Orserdu

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Dose-limiting Toxicity When Administered MEN2312

    Time frame: Baseline through Day 28

  2. Recommended Phase 2 Dose (RP2D) of MEN2312

    Time frame: Baseline through Month 6

Secondary outcomes

  1. Overall Response Rate (ORR)

    Time frame: Baseline through 28 days after the last treatment administration (up to approximately 7 months)

  2. Duration of Response (DOR)

    Time frame: Baseline through 28 days after the last treatment administration (up to approximately 7 months)

  3. Clinical Benefit Rate (CBR)

    Time frame: Baseline through 28 days after the last treatment administration (up to approximately 7 months)

  4. Progression-free Survival (PFS)

    Time frame: Baseline through 28 days after the last treatment administration (up to approximately 7 months)

  5. Overall Survival (OS)

    Time frame: Baseline through 3 months after the last treatment administration (up to approximately 9 months)

  6. Time to Response (TTR)

    Time frame: Baseline through 28 days after the last treatment administration (up to approximately 7 months)

  7. Area Under the Plasma Concentration-time Curve (AUC) of MEN2312 When Administered as Monotherapy

    Time frame: Up to 6 months post dose

  8. AUC of MEN2312 When Administered as Combination Therapy

    Time frame: Up to 6 months post dose

  9. Amount of MEN2312 Excreted in Urine When Administered as Monotherapy

    Time frame: Up to 2 months post dose

  10. Comparison of Plasma Concentration of MEN2312 Monotherapy With MEN2312 Combination Therapy

    Time frame: Up to 6 months post dose

07

Study locations

47 of 47 sites recruiting
  • Highlands Oncology Group
    Springdale, Arkansas 72703, United States
    Recruiting
    • Joseph Beck, MD · Principal investigator
  • City of Hope
    Duarte, California 31010, United States
    Recruiting
    • Hope Rugo · Principal investigator
  • UC San Diego Moores Cancer Center
    La Jolla, California 92093-0698, United States
    Recruiting
    • Rebecca Shatsky · Principal investigator
  • Stanford Cancer Center
    Palo Alto, California 94304, United States
    Recruiting
    • Jennifer L Caswell-Jin · Principal investigator
  • UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco, California 94158, United States
    Recruiting
    • Amy Chien · Principal investigator
  • UCLA Hematology Oncology - Parkside
    Santa Monica, California 90404, United States
    Recruiting
    • Aditya Bardia, MD, MPH · Principal investigator
  • Yale Comprehensive Cancer Center
    New Haven, Connecticut 06511, United States
    Recruiting
    • Patricia LoRusso, DO · Principal investigator
  • Advent Health Orlando
    Altamonte Springs, Florida 32701, United States
    Recruiting
    • Wassim Mchayleh, MD · Principal investigator
  • Sarah Cannon Research Institute at Florida Cancer Specialists
    Orlando, Florida 32827, United States
    Recruiting
    • Cesar Perez Batista, MD · Principal investigator
  • Florida Cancer Specialists & Research Institute (FCS) - Sarasota
    Sarasota, Florida 34232, United States
    Recruiting
    • Judy Wang, MD · Principal investigator
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
    Recruiting
    • Hatem Soliman · Principal investigator
  • Winship Cancer Institute, Emory University
    Atlanta, Georgia 30322, United States
    Recruiting
    • Manali Bhave · Principal investigator
  • University of Illinois Hospital and Health Sciences System (Outpatient Cancer Center)
    Chicago, Illinois 60612, United States
    Recruiting
    • Oana Danciu · Principal investigator
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
    Recruiting
    • Nan Chen · Principal investigator
  • University of Iowa Health Care
    Iowa City, Iowa 52242, United States
    Recruiting
    • Mark Burkard · Principal investigator
  • The University of Kansas Cancer Center
    Fairway, Kansas 66205, United States
    Recruiting
    • Priyanka Sharma · Principal investigator
  • Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland 21287, United States
    Recruiting
    • Jessica Tao, MD · Principal investigator
  • Massachusetts General Hospital Cancer Center
    Boston, Massachusetts 02114, United States
    Recruiting
    • Seth Wander, MD, PhD · Principal investigator
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
    Recruiting
    • Antonio Giordano, MD, PhD · Principal investigator
  • START Midwest - Oncology
    Grand Rapids, Michigan 49546, United States
    Recruiting
    • Manish Sharma, MD · Principal investigator
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
    Recruiting
    • Karthik Giridhar · Principal investigator
  • Astera Cancer Care
    East Brunswick, New Jersey 08816, United States
    Recruiting
    • Siu-Long Yao · Principal investigator
  • Perlmutter Cancer Center - Sunset Park
    Brooklyn, New York 11220, United States
    Recruiting
    • Nancy Chan · Principal investigator
  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island
    Mineola, New York 11501, United States
    Recruiting
    • Nancy Chan · Principal investigator
  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
    New York, New York 10016, United States
    Recruiting
    • Nancy Chan · Principal investigator
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Sherry Shen · Principal investigator
  • Providence Cancer Institute Franz Clinic
    Portland, Oregon 97213, United States
    Recruiting
    • David Page · Principal investigator
  • The West Clinic, PC dba West Cancer Center
    Germantown, Tennessee 38138, United States
    Recruiting
    • Gregory Vidal · Principal investigator
  • SCRI Oncology Partners Group
    Nashville, Tennessee 37203, United States
    Recruiting
    • Erika P Hamilton, MD · Principal investigator
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
    Recruiting
    • Heather McArthur · Principal investigator
  • The University of Texas M.D. Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
    • Jason Mouabbi, MD · Principal investigator
  • START San Antonio, LLC
    San Antonio, Texas 78229, United States
    Recruiting
    • Amita Patnaik, MD · Principal investigator
  • University of Texas Health Science Center San Antonio
    San Antonio, Texas 78229, United States
    Recruiting
    • Virginia Kaklamani, MD · Principal investigator
  • START Mountain
    West Valley City, Utah 84119, United States
    Recruiting
    • William McKean, MD, PhD · Principal investigator
  • NEXT Virginia
    Fairfax, Virginia 22031, United States
    Recruiting
    • Alexander Spira, MD, PhD · Principal investigator
  • University of Wisconsin Carbone Cancer Center
    Madison, Wisconsin 53792, United States
    Recruiting
    • Kari Wisinksi · Principal investigator
  • Froedtert Hospital & the Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
    Recruiting
    • Lubna Chaudhary · Principal investigator
  • Alexandra Cortegoso Mosquera
    Santiago de Compostela, A Coruña 15706, Spain
    Recruiting
  • Maria Martinez Garcia
    Barcelona, 08003, Spain
    Recruiting
  • Hospital Universitario Vall d'Hebron - Vall d'Hebron Institute of Oncology (VHIO) Medical Oncology Department
    Barcelona, 08035, Spain
    Recruiting
    • Cristina Saura Manich · Principal investigator
  • IOB - Madrid Fundacion Hermanas Hospitalarias (Hospital Beata Maria Ana)
    Madrid, 28007, Spain
    Recruiting
    • Javier C Castán · Principal investigator
  • START Madrid - Hospital Universitario Fundacion Jimenez Diaz
    Madrid, 28040, Spain
    Recruiting
    • Bernard Doger de Spevill-Uribe · Principal investigator
  • Hospital Universitario 12 Octubre Servico de Oncologia Medica
    Madrid, 28041, Spain
    Recruiting
    • Manuel Alva Bianchi · Principal investigator
  • START Madrid - Centro Integral Oncologico Clara Campal (CIOCC), Hospital HM Sanchinarro
    Madrid, 28050, Spain
    Recruiting
    • Irene M Candilejo · Principal investigator
  • Hospital Clinico San Carlos
    Madrid, 484816, Spain
    Recruiting
    • Garcia Saenz · Principal investigator
  • Hospital Clinico Universitario De Valencia Oncologia Medica
    Valencia, 46010, Spain
    Recruiting
    • Juan Miguel Cejalvo Andjuar · Principal investigator
  • Hospital Universitario y Politecnico La Fe Oncologia Medica
    Valencia, 46026, Spain
    Recruiting
    • Ana Santaballa Bertran · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Oct 2027, 35 months after the start.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 35 months is below that.

Counting every sponsor, half of 762 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2024
First posted
Oct 15, 2024
StartActual
Oct 25, 2024
Primary completionEst.
Oct 24, 2027
CompletionEst.
Oct 23, 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 Spain)
  • Alexandra Cortegoso Mosquera · Santiago de Compostela, Spain
  • Maria Martinez Garcia · Barcelona, Spain
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    2 sites added
    Show 2 added (2 Spain)
    • Alexandra Cortegoso Mosquera · Santiago de Compostela, Spain
    • Maria Martinez Garcia · Barcelona, Spain
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06638307
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Oct 25, 2024
Primary completion
Oct 24, 2027 (estimated)
Completion
Oct 23, 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Stemline Trials
Contact
clinicaltrials@menarinistemline.com
1-877-332-7961

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion